



Mitsui Chemicals

Shiodome City Center 1-5-2, Higashi-Shimbashi, Minato-ku, Tokyo 105-7122, Japan
<http://group.mitsuichemicals.com>

NEWS RELEASE

MITSUI CHEMICALS, INC.

January 26, 2021

Mitsui Chemicals Named 2019 Best Supplier by Swiss-Based Debiopharm

Award recognizes Mitsui Chemicals' long contribution in supplying PLGA for injectable, sustained-release drugs

Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu) is pleased to announce it has received the 2019 Best Supplier Award from Swiss-headquartered global pharmaceutical manufacturer Debiopharm (Martigny, Switzerland; CEO: Bertrand Ducrey). The honor was officially conferred in an online ceremony held on December 11, 2020.

Mitsui Chemicals has for many years supplied Debiopharm with polylactic-co-glycolic acid (PLGA), a key ingredient in the Swiss company's mainstay controlled-release triptorelin preparations. Debiopharm praised Mitsui Chemicals for ensuring a stable supply and achieving quality improvements over this time, thereby contributing to the global success of Debiopharm's triptorelin business.



“Debiopharm and Mitsui have been partnering for many years,” said Cedric Sager, CEO, Debiopharm Research & Manufacturing S.A. “Both companies have progressed together in terms of quality and operational excellence. We thank Mitsui for its continued commitment to Debiopharm.”

“It is a great honor for Mitsui Chemicals to be awarded as the Best Supplier of the year 2019 by Debiopharm,” said TOGASHI Kazuhiko, General Manager, Personal Care Materials Division, Mitsui Chemicals. “We promise we will make our best efforts to maintain the stable supply and improve the quality.”

■ **PLGA™**: <https://jp.mitsuichemicals.com/en/service/healthcare/personal/plga/index.htm>

■ **Debiopharm**: <https://www.debiopharm.com/>

A global pharmaceutical manufacturer headquartered in Switzerland, Debiopharm is a world leader in PLGA-based injectable sustained-release technology. The active ingredient encapsulated in the PLGA polymer is gradually released into the patient's bloodstream, maintaining its efficacy for one to six months. Debiopharm's injectable controlled-release formulations of triptorelin are currently marketed in more than 90 countries for the treatment of prostate cancer and endometriosis.

###